Hinova Pharmaceuticals (SHSE:688302) Cash Flow for Dividends: ¥-0.64 Mil (TTM As of Mar. 2026)


SHSE:688302 Hinova Pharmaceuticals Inc SHSE:688302
26 GF Score
Price ¥39.40
! 2 Warning Signs
View Full Analysis

What is Hinova Pharmaceuticals Cash Flow for Dividends?

Hinova Pharmaceuticals SHSE:688302 +3.77% 26 Cash Flow for Dividends is ¥-0.64 Mil as of Mar. 2026. GuruFocus rates SHSE:688302 with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Hinova Pharmaceuticals's cash flow for dividends for the three months ended in Mar. 2026 was ¥-0.64 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-0.64 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Hinova Pharmaceuticals's quarterly payment of dividends stayed the same from Sep. 2025 (¥0.00 Mil) to Dec. 2025 (¥0.00 Mil) but then increased from Dec. 2025 (¥0.00 Mil) to Mar. 2026 (¥-0.64 Mil).

Hinova Pharmaceuticals's annual payment of dividends declined from Dec. 2023 (¥-0.90 Mil) to Dec. 2024 (¥0.00 Mil) but then increased from Dec. 2024 (¥0.00 Mil) to Dec. 2025 (¥-1.24 Mil).

Hinova Pharmaceuticals Cash Flow for Dividends Related Terms

Hinova Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Hinova Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hinova Pharmaceuticals Cash Flow for Dividends Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial -2.56 -3.92 -0.90 0.00 -1.24

Hinova Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.64
SHSE:688302
26GF Score
Hinova Pharmaceuticals Inc SHSE:688302
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hinova Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of ¥-0.64 Mil mean?
Hinova Pharmaceuticals (SHSE:688302) has a Cash Flow for Dividends of ¥-0.64 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Hinova Pharmaceuticals and its competitors.
Is Hinova Pharmaceuticals' Cash Flow for Dividends too high?
Hinova Pharmaceuticals' current Cash Flow for Dividends is ¥-0.64 Mil. Overall, Hinova Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Cash Flow for Dividends compare to VRTX and REGN?
Hinova Pharmaceuticals' Cash Flow for Dividends of ¥-0.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Hinova Pharmaceuticals and its competitors. Hinova Pharmaceuticals's current Cash Flow for Dividends is ¥-0.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Cash Flow for Dividends of ¥-0.64 Mil. The current Cash Flow for Dividends is ¥-0.64 Mil. Hinova Pharmaceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Cash Flow for Dividends is ¥-0.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hinova Pharmaceuticals Business Description

Address No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
26GF Score

Get the complete analysis for SHSE:688302

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥39.40
Price